Reino Heikkilä

  • Head of section
  • +47 22 93 54 27

Publications 2021

Gjersvik P, Heikkila R, Johansen TEB (2021)
Rescue treatment for cancer
Tidsskr. Nor. Laegeforen., 141 (5), 487

Heikkilä R, Myklebust TÅ, Møller B (2021)
Regional variation in cancer survival in Norway
Cancer Epidemiol, 75, 102038
DOI 10.1016/j.canep.2021.102038, PubMed 34571393

Publications 2020

De Bruycker A, Spiessens A, Dirix P, Koutsouvelis N, Semac I, Liefhooghe N, Gomez-Iturriaga A, Everaerts W, Otte F, Papachristofilou A, Scorsetti M, Shelan M, Siva S, Ameye F, Guckenberger M, Heikkilä R, Putora PM, Zapatero A, Conde-Moreno A, Couñago F, Vanhoutte F, Goetghebeur E, Reynders D, Zilli T, Ost P (2020)
PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial
BMC Cancer, 20 (1), 406
DOI 10.1186/s12885-020-06911-4, PubMed 32398040

Zilli T, Dirix P, Heikkilä R, Liefhooghe N, Siva S, Gomez-Iturriaga A, Everaerts W, Otte F, Shelan M, Mercier C, Achard V, Thon K, Stellamans K, Moon D, Conde-Moreno A, Papachristofilou A, Scorsetti M, Gückenberger M, Ameye F, Zapatero A, Van De Voorde L, López Campos F, Couñago F, Jaccard M, Spiessens A et al. (2020)
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases
Eur Urol Focus, 7 (2), 241-244
DOI 10.1016/j.euf.2020.12.010, PubMed 33386290

Publications 2018

Oltedal S, Kørner H, Aasprong OG, Hussain I, Tjensvoll K, Smaaland R, Søreide JA, Søreide K, Lothe RA, Heikkilä R, Gilje B, Nordgård O (2018)
The Prognostic Relevance of Sentinel Lymph Node Metastases Assessed by PHGR1 mRNA Quantification in Stage I to III Colon Cancer
Transl Oncol, 11 (2), 436-443
DOI 10.1016/j.tranon.2018.01.015, PubMed 29475140

Oltedal S, Skaland I, Maple-Grødem J, Tjensvoll K, Janssen EAM, Gilje B, Smaaland R, Heikkilä R, Nordgård O (2018)
Expression profiling and intracellular localization studies of the novel Proline-, Histidine-, and Glycine-rich protein 1 suggest an essential role in gastro-intestinal epithelium and a potential clinical application in colorectal cancer diagnostics
BMC Gastroenterol, 18 (1), 26
DOI 10.1186/s12876-018-0752-8, PubMed 29415677

Publications 2017

Heikkilä R, Kaasa S (2017)
Chemotherapy in end-of-life care
Ann Oncol, 28 (4), 684-685
DOI 10.1093/annonc/mdx039, PubMed 28327919

Publications 2012

Nordgård O, Oltedal S, Aasprong OG, Søreide JA, Søreide K, Tjensvoll K, Gilje B, Heikkilä R, Guriby M, Lothe RA, Smaaland R, Kørner H (2012)
Prognostic relevance of occult metastases detected by cytokeratin 20 and mucin 2 mRNA levels in sentinel lymph nodes from colon cancer patients
Ann Surg Oncol, 19 (12), 3719-26
DOI 10.1245/s10434-012-2454-8, PubMed 22752373

Publications 2011

Oltedal S, Aasprong OG, Møller JH, Kørner H, Gilje B, Tjensvoll K, Birkemeyer EM, Heikkilä R, Smaaland R, Nordgård O (2011)
Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy
Int J Colorectal Dis, 26 (10), 1271-7
DOI 10.1007/s00384-011-1233-5, PubMed 21573767

Publications 2010

Oltedal S, Gilje B, Kørner H, Aasprong OG, Tjensvoll K, Heikkilä R, Smaaland R, Nordgård O (2010)
Detection of occult metastases in sentinel lymph nodes from colon cancer patients by K-ras mutation peptide nucleic acid clamp PCR
Ann Surg, 251 (6), 1087-91
DOI 10.1097/SLA.0b013e3181dae1bc, PubMed 20485143

Tjensvoll K, Oltedal S, Farmen RK, Shammas FV, Heikkilä R, Kvaløy JT, Gilje B, Smaaland R, Nordgård O (2010)
Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients
Clin Breast Cancer, 10 (5), 378-84
DOI 10.3816/CBC.2010.n.050, PubMed 20920982

Publications 2009

Nordgård O, Oltedal S, Kørner H, Aasprong OG, Tjensvoll K, Gilje B, Heikkilä R (2009)
The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR
Int J Colorectal Dis, 24 (3), 261-8
DOI 10.1007/s00384-008-0613-y, PubMed 19119477

Nordgård O, Oltedal S, Kørner H, Aasprong OG, Tjensvoll K, Gilje B, Heikkilä R (2009)
Quantitative RT-PCR detection of tumor cells in sentinel lymph nodes isolated from colon cancer patients with an ex vivo approach
Ann Surg, 249 (4), 602-7
DOI 10.1097/SLA.0b013e31819ec923, PubMed 19300229

Publications 2008

Gilje B, Heikkilä R, Oltedal S, Tjensvoll K, Nordgård O (2008)
High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations
J Mol Diagn, 10 (4), 325-31
DOI 10.2353/jmoldx.2008.070183, PubMed 18556764

Glimelius B, Sørbye H, Balteskard L, Byström P, Pfeiffer P, Tveit K, Heikkilä R, Keldsen N, Albertsson M, Starkhammar H, Garmo H, Berglund A (2008)
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
Ann Oncol, 19 (5), 909-14
DOI 10.1093/annonc/mdm588, PubMed 18209013

Tjensvoll K, Gilje B, Oltedal S, Shammas VF, Kvaløy JT, Heikkilä R, Nordgård O (2008)
A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow
Breast Cancer Res Treat, 116 (2), 329-38
DOI 10.1007/s10549-008-0204-1, PubMed 18846421

Publications 2007

Farmen RK, Nordgård O, Gilje B, Shammas FV, Kvaløy JT, Oltedal S, Heikkilä R (2007)
Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients
Breast Cancer Res Treat, 108 (2), 251-8
DOI 10.1007/s10549-007-9592-x, PubMed 17492378

Page visits: 3347